Over the past 30 years, New York Oncology Hematology patients have participated in clinical drug trials leading to FDA approval of 50 new cancer therapies. With the largest, most comprehensive clinical research operation in the region, NYOH is constantly offering eligible patients opportunities to join new trials.
Clinical trials are human research studies, conducted with volunteers who participate in the testing of new therapies. The purpose is finding new, more effective cancer treatment. NYOH is the largest organization in the area that participates in Phase I/II and III trials, including those for all major solid tumor types, hematologic malignancies and supportive care.
NYOH is committed to delivering high-quality, ethically conducted, world-class clinical research trials and superior research support services to promote the scientific advancement of cancer care as we offer our patients access to breakthrough treatments close to home.
Through our affiliation with The US Oncology Network, one of the largest and most reputable community-based research networks in the world, NYOH has access to some of the most promising new trials being offered. We also participate in National Cancer Institute (NCI) sponsored research.
At New York Oncology Hematology, we are proud of our role in the research and development of vital new cancer therapies. And we are deeply committed to bringing clinical trials to our community, offering patients an opportunity to help shape the future of cancer treatment, while benefitting from the very latest in clinical trials.
Over the past two decades, more than 3,000 NYOH patients have participated in clinical drug trials leading to FDA approval of 50 new cancer therapies:
|
Abraxane |
Keytruda |
To learn more about a study or to refer an eligible patient, please call 518-489-3612 ext. 1014 or email us.
©2024 New York Oncology Hematology. All rights reserved.